UAE sets up $150M biologics plant

Abu Dhabi, which is part of the United Arab Emirates, is setting up $150 million biologics manufacturing plant that will produce crystal insulin for diabetes, anti-cancers, vaccines, haemophilia A and growth factors for the Middle East and North Africa. The plant is part of the region's plan to expand its industry beyond oil. Report

Suggested Articles

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.

Merck will apply its vaccine capabilities to an asset based on Themis’ measles vector platform that is set to enter the clinic this year.